Special Issue

From Progression to Metastasis of Solid Cancer

Message from the Guest Editors

Dear colleagues, Tumor growth is driven by oncogenic and epigenetic alterations that select for aggressive clones through Darwinian competition in conjunction with the surrounding ecosystem, particularly the tumor immune microenvironment (TIME). While some clones dominate the primary lesion, others may sprout DTCs. and should be preferentially targeted for therapy. The biology of DTCs, their metabolism, dormancy, plasticity (epithelial-mesenchymal and mesenchymal-epithelial transitions as well as stemness) and competence to reenter the cell cycle at distal sites are critical for metastasis. They also impact drug resistance and relapse. This special issue of *Cancers* invites original studies that expose novel mechanisms of solid cancer progression and metastasis, with an eve on novel therapeutic targeting. In particular, we welcome articles that analyze oncogenic processes that promote tumor invasion, dissemination, tumor-TIME interactions, DTCs, and the response to therapy in the primary, invasive front, hematogenous, and metastatic niches using clinical data and preclinical animal models.

Guest Editors

Prof. Dr. Eldad Zacksenhaus

Toronto General Research Institute, University Health Network, 67 College Street, Toronto, ON M5G 2M1, Canada

Prof. Sean Egan

1. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

2. Program in Cell Biology, The Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada

Deadline for manuscript submissions

closed (20 May 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/67129

Cancers MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cancers@mdpi.com

mdpi.com/journal/

cancers







an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



cancers



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)